DLB — Dolby Laboratories Balance Sheet
0.000.00%
- $7.30bn
- $6.79bn
- $1.27bn
- 96
- 34
- 87
- 85
Annual balance sheet for Dolby Laboratories, fiscal year end - September 27th, USD millions except per share, conversion factor applied.
2020 September 25th | 2021 September 24th | 2022 September 30th | 2023 September 29th | 2024 September 27th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,119 | 1,264 | 809 | 885 | 482 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 342 | 415 | 420 | 444 | 513 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,547 | 1,760 | 1,311 | 1,488 | 1,194 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 618 | 602 | 560 | 522 | 518 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 2,917 | 3,106 | 2,690 | 2,980 | 3,110 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 267 | 316 | 278 | 422 | 418 |
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 485 | 508 | 443 | 625 | 633 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 2,433 | 2,598 | 2,246 | 2,355 | 2,477 |
Total Liabilities & Shareholders' Equity | 2,917 | 3,106 | 2,690 | 2,980 | 3,110 |
Total Common Shares Outstanding |